Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amplify Transformational Data Sharing ETF (BLOK) vs GSK plc (GSK) Price & Performance

Amplify Transformational Data Sharing ETFTrade

Price performance (Past 24H)

Key statistics

Amplify Transformational Data Sharing ETF vs GSK plc — how do they compare? Amplify Transformational Data Sharing ETF trades at $59.99, while GSK plc trades at $50.42 (market cap $102.60B). The key difference: GSK plc pays a 3.57% dividend while Amplify Transformational Data Sharing ETF pays none. Which is the better fit depends on your goals.

BLOKGSK
52-Week High
$74.10$61.18
52-Week Low
$47.36$38.22
Market Cap
$102.60B
Sector
Health
Enterprise Value
$123.04B
Dividend Yield
3.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amplify Transformational Data Sharing ETF

BLOK trades at $60.00, up 1.56% today, but faces bearish technical signals with 14 sell indicators versus 2 buy signals. The stock shows neutral momentum oscillators while moving averages signal downward pressure. Recent institutional activity shows Dynamic Advisor Solutions reduced its position by 81.1% in Q2 2026. The ETF focuses on transformational data sharing companies with exposure to AI infrastructure and blockchain economy participants.

The outlook remains cautious given bearish technical indicators and institutional selling. Investment opportunity exists in the ETF's diversified exposure to data sharing and AI infrastructure growth, but risks include sector volatility and competitive ETF pressure. The dividend of $0.08 scheduled for June 2026 provides minor income support amid uncertain market conditions.

GSK plc

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amplify Transformational Data Sharing ETF

The fund is an actively managed ETF that seeks to provide total return by investing at least 80% of its net assets in the equity securities of companies actively involved in the development and utilization of "transformational data sharing technologies". It may invest in non-US equity securities, including depositary receipts.

Read more on BLOK

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK